Axovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the Mesa
September 25 2019 - 4:05PM
Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage
company developing innovative gene therapies, today announced that
Parag Meswani, Pharm.D., senior vice president, commercial strategy
& operations, will present at the annual Cell & Gene
Meeting on the Mesa at 4:30 PM PT on October 3, 2019 in Carlsbad,
California.
Organized by the Alliance for Regenerative Medicine, the Cell
& Gene Meeting on the Mesa is a three-day conference featuring
more than 80 dedicated company presentations by leading public and
private companies, highlighting technical and clinical achievements
over the past 12 months in the areas of cell therapy, gene therapy,
gene editing, tissue engineering, and broader regenerative medicine
technologies, as well as over 100 panelists and featured
speakers.
A live video webcast of all company presentations will be
available at: http://www.meetingonthemesa.com/webcast and will also
be published on the conference website shortly after the
event. Please visit www.meetingonthemesa.com for full
information including registration.
About AxovantAxovant, part of the Roivant
family of companies, is a clinical-stage gene therapy company
focused on developing a pipeline of innovative product candidates
for debilitating neurological and neuromuscular diseases. Our
current pipeline of gene therapy candidates targets GM1
gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and
Sandhoff disease), and Parkinson’s disease. Axovant is focused on
accelerating product candidates into and through clinical trials
with a team of experts in gene therapy development and through
external partnerships with leading gene therapy organizations. For
more information, visit www.axovant.com.
About RoivantRoivant Sciences aims to improve
health by rapidly delivering innovative medicines and technologies
to patients. It does this by building Vants – nimble,
entrepreneurial biotech and healthcare technology companies with a
unique approach to sourcing talent, aligning incentives, and
deploying technology to drive greater efficiency in R&D and
commercialization. For more information, please
visit www.roivant.com.
Contacts:Media and
InvestorsParag V. Meswani, Pharm.D. (212) 547-2523
media@axovant.com investors@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jul 2023 to Jul 2024